Experienced in Collagenous Colitis

Dr. Ricardo M. Mccall

Gastroenterology
Parkview Health System Inc
11104 Parkview Circle Dr, Suite 310, 
Fort Wayne, IN 
 (707.4 mi)
Accepting New Patients
Experienced in Collagenous Colitis
Parkview Health System Inc
11104 Parkview Circle Dr, Suite 310, 
Fort Wayne, IN 
 (707.4 mi)
OverviewInsuranceLocationsClinical Research

Overview

Ricardo Mccall is a Gastroenterologist in Fort Wayne, Indiana. Dr. Mccall and is rated as an Experienced provider by MediFind in the treatment of Collagenous Colitis. His top areas of expertise are Diverticular Disease, Diarrhea, Trichohepatoenteric Syndrome, Endoscopy, and Colonoscopy. Dr. Mccall is currently accepting new patients.

His clinical research consists of participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gastroenterology
Licenses
Internal Medicine in LA
Hospital Affiliations
Parkview Regional Medical Center
Akron General Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Humana

Locations

PARKVIEW HEALTH SYSTEM INC
11104 Parkview Circle Dr, Suite 310, Fort Wayne, IN 46845

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Active_not_recruiting
Publish Date: July 03, 2024
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
A Phase 3 Long-term Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)
Enrollment Status: Completed
Publish Date: June 21, 2024
Intervention Type: Drug
Study Drug: Ontamalimab
Study Phase: Phase 3
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Other
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Clinical Validation of An Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, for Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 01, 2023
Intervention Type: Procedure, Diagnostic test
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 307)
Enrollment Status: Terminated
Publish Date: March 31, 2022
Intervention Type: Drug, Other
Study Drug: Ontamalimab
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 303)
Enrollment Status: Completed
Publish Date: January 14, 2022
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 301)
Enrollment Status: Terminated
Publish Date: June 14, 2021
Intervention Type: Other, Drug
Study Phase: Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Crohn's Disease (CARMEN CD 305)
Enrollment Status: Terminated
Publish Date: April 29, 2021
Intervention Type: Other, Biological
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Advanced in Collagenous Colitis
Dr. Ross Heil
Gastroenterology
Advanced in Collagenous Colitis
Dr. Ross Heil
Gastroenterology

Goshen Health System Inc

2824 Elkhart Rd, Goshen Physicians Diagnostics, 
Goshen, IN 
 (49.6 mi)
574-535-1700
Experience:
16+ years
Languages Spoken:
English
See accepted insurances

Ross Heil is a Gastroenterologist in Goshen, Indiana. Dr. Heil has been practicing medicine for over 16 years and is rated as an Advanced provider by MediFind in the treatment of Collagenous Colitis. His top areas of expertise are Ulcerative Colitis, Familial Adenomatous Polyposis, Colitis, Gastrectomy, and Colonoscopy.

Experienced in Collagenous Colitis
Dr. Dan Mccance
Gastroenterology
Experienced in Collagenous Colitis
Dr. Dan Mccance
Gastroenterology

Hillsdale Community Health Center

168 S Howell St, 
Hillsdale, MI 
 (55.7 mi)
517-437-4451
Languages Spoken:
English
See accepted insurances

Dan Mccance is a Gastroenterologist in Hillsdale, Michigan. Dr. Mccance and is rated as an Advanced provider by MediFind in the treatment of Collagenous Colitis. His top areas of expertise are Chronic Erosive Gastritis, Colitis, Diarrhea, Endoscopy, and Gastrectomy.

Experienced in Collagenous Colitis
Dr. Lokesh Jha
Gastroenterology
Experienced in Collagenous Colitis
Dr. Lokesh Jha
Gastroenterology

Parkview Health System Inc

11104 Parkview Circle Dr, 
Fort Wayne, IN 
206-266-5400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lokesh Jha is a Gastroenterologist in Fort Wayne, Indiana. Dr. Jha and is rated as an Advanced provider by MediFind in the treatment of Collagenous Colitis. His top areas of expertise are Gastroesophageal Reflux Disease (GERD), Painful Swallowing, Swallowing Difficulty, Endoscopy, and Gastrectomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile